Gun-Wook Kang
Direktor/Vorstandsmitglied bei KOREA UNITED PHARM INC.
Aktive Positionen von Gun-Wook Kang
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KOREA UNITED PHARM INC. | Direktor/Vorstandsmitglied | - | - |
| Independent Dir/Board Member | - | - | |
| Seoul National University | Corporate Officer/Principal | - | - |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Direktor/Vorstandsmitglied | - | - |
| Independent Dir/Board Member | - | - |
Karriereverlauf von Gun-Wook Kang
Statistik
International
| Südkorea | 4 |
Operativ
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KOREA UNITED PHARM INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Pelemed Co., Ltd.
Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Health Technology |
- Börse
- Insiders
- Gun-Wook Kang
- Erfahrung
